The Organizing Committee of the San Antonio Breast Cancer Symposium® welcomes you to the Best of SABCS® Chicago 2020 - incorporating the 17th Annual Bench to Bedside - chaired by Dr. Kathy S. Albain, MD, FACP, FASCO, to be held on February 1st, 2020.
The University of Texas at San Antonio and Dr. Kathy S. Albain of Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center, are pleased to announce the 2020 17th Annual Best of San Antonio Breast Cancer Symposium®: Bench to Bedside Continuing Education Program. This half-day scientific meeting will be a continuation of the long-standing history of quality education provided by Dr. Albain and her expert faculty by providing a critical review of the University of Texas at San Antonio’s annual San Antonio Breast Cancer Symposium® . This highly regarded program will continue to meet the educational needs of the practicing community and academic oncologists as well as other healthcare professionals involved and/or interested the therapeutic management of patients with breast cancer or in breast cancer prevention and survivorship. SABCS®, now in its 42nd year, is the premier conference forbasic, translational and clinical cancer research professionals. It is well known for presenting the latest breast cancer data from all over the world.
The Best of SABCS® allows professionals who unable to travel to San Antonio, as well as those who seek a concise critical review, the opportunity to hear expert multidisciplinary faculty review and place in context conference highlights, as originally presented at SABCS® 2019, in a half-day program. Attendees will learn the current advances in breast cancer research that are changing clinical practice for the benefit of patients as well as exciting translational science soon to impact breast cancer care in the near future.
A special discount has been negotiated for previous attendees to Bench to Bedside as well as for members of the Indiana Oncology Society (IOS). Residents, fellows and nurse practitioners may attend at no charge prior registration.
We would like to extend recognition and thanks to the supporters of the Best of SABCS® for understanding the importance of this education and making it possible to organize this very valuable educational activity.
We encourage and look forward to your attendance; please register early to secure a place.
Program Director: Virginia G. Kaklamani, MD, DSc, UT Health Science Center San Antonio.
Regional Director: Kathy S. Albain, MD, FACP, FASCO, Loyola Univeristy Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center.
These regional symposia are directed to academic and community physicians, medical residents and fellows training in oncology subspecialties, physician assistants, nurse practitioners and basic/translational researchers involved in breast cancer. Specialties include medical, surgical, gynecologic, and radiation oncology, as well as other pertinent healthcare professionals involved in breast cancer medicine.
The Long School of Medicine designates this live activity up to a maximum of 4.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Identify factors that predispose individuals and increase the risk of developing breast cancer
• Describe prognostic and predictive molecular signatures and biomarkers that can identify the most appropriate treatment strategies for individuals with breast cancer.
• Discuss scientific advances from the laboratory that have great potential to translate into increased knowledge of breast cancer biology and pathogenesis.
• Review new results from clinical trials in all aspects of breast cancer care presented during oral, poster and educational sessions at the annual San Antonio Breast Cancer Symposium®.
• Discuss on results of evidence from preclinical research and clinical trials that support the rational combinations of traditional and newer pharmacologic interventions, with a focus on novel therapeutics and resistance mechanisms.
• Develop appropriate individualized treatment strategies for those patients who would benefit from new treatments in all the major subtypes of breast cancer and also focus on reversing resistance to commonly used therapies.
Education to improve physician understanding of the latest trial data, guidelines, and applications in clinical practice has been identified as a vehicle for closing the knowledge gap and helping to improve patient outcomes [Christian 2006]. This proposed CME symposium will address the above gaps in clinical practice/knowledge between what is known and what healthcare practitioners wish to better understand regarding the screening, diagnosis, and management of patient with BC. In addition, it will focus on identified research/presentations from SABCS® 2019 that cover these issues, including results of BC research, facilitating the rapid translation of new knowledge into better care for breast cancer patients and addressing issues such as axillary management in primary BC, human epidermal growth factor receptor 2 (HER2), cell cycle regulation with CDK inhibitors, genomic heterogeneity, and proteomic analysis of BC.
|Contact No. :||+1 443-370-2698
|Registration Type||Last Date||Price|
|Early Fee||29 Jan,2020||USD 75.00|
|IOS Member Fee||31 Jan,2020||USD 25.00|
|Fellow, Resident, Nurse Practitioner Fee||31 Jan,2020||Free|
|Industry Attendees Early Fee||29 Jan,2020||USD 100.00|